PMED-1 is a β-catenin inhibitor that significantly reduces β-catenin activity in hepatoblastoma cells and various HCC cells, with an IC 50 value ranging from 4.87 to 32 μM. PMED-1 affects Wnt signaling by decreasing the interaction between β-catenin and CREB binding protein, thereby inhibiting cell proliferation. PMED-1 has potential applications in cancer research.